ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Chief Executive Officer

Schlieren, Switzerland, January 5, 2026- ImmunOs Therapeutics AG is pleased to announce that Hilmar Ebersbach, former Chief Scientific Officer of the Company, has been nominated as Chief Executive Officer, effective January 2026. Hilmar brings deep scientific expertise, a strong track record in drug discovery including translational development as well as a clear focus on operational excellence and disciplined execution. His intimate knowledge of ImmunOs’ pipeline, biomarker strategy, and clinical programs positions him to drive efficient capital allocation, accelerate value inflection points, and advance the Company’s programs toward meaningful clinical and strategic milestones. “I’m incredibly excited and honored to be nominated as CEO of ImmunOs starting January 2026.” Said Dr. Hilmar Ebersbach, Chief Executive Officer of ImmunOs Therapeutics AG. “ Thank you to the Board and the entire team for the trust and I’m looking forward to shaping the next chapter together.“

About ImmunOs Therapeutics AG

ImmunOs Therapeutics AG leverages its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases. ImmunOs’ lead program is a multi-functional HLA-fusion protein that binds specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and can stimulate both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs is also developing different modalities to agonize receptors for the modulation of the immune system in inflammatory diseases. The Company is supported by leading international investors and is located in Schlieren, Switzerland. For more information, please visit www.immunostherapeutics.com. Company Contact ImmunOs Therapeutics AG Wagistrasse 18 8952 Schlieren (Zurich Area), Switzerland info@immunostherapeutics.com